Search

Your search keyword '"Cabioglu N"' showing total 171 results
Start Over Author "Cabioglu N"
171 results on '"Cabioglu N"'

1. Favorable outcome with sentinel lymph node biopsy alone after neoadjuvant chemotherapy in clinically node positive breast cancer at diagnosis: Turkish Multicentric NEOSENTI-TURK MF-18-02-study

Author

Cabıoğlu, N., Karanlık, H., Yıldırım, N., Müslümanoğlu, M., Çakmak Karadeniz, G., Trabulus Can, D., Tükenmez, M., Ersoy, Y.E., Uras, C., Zengel, B., Emiroğlu, S., Polat, A.K., Yeniay, L., Özkurt, E., Kara, H., İbiş, K., Aydıner, A., Özmen, V., and İğci, A.

Published
2021
Full Text
View/download PDF

5. The effect of primary surgery in patients with stage IV breast cancer with bone metastasis only (protocol bomet MF14-01); a multi-center, registry study

Author

Soran, A., primary, Dogan, L., additional, Ozbas, S., additional, Isık, A., additional, Trablus, D., additional, Demirci, U., additional, Karanlık, H., additional, Soyder, A., additional, Dag, A., additional, Bilici, A., additional, Dogan, M., additional, Koksal, H., additional, Sendur, M.A.N., additional, Gulcelik, M.A., additional, Maralcan, G., additional, Cabioglu, N., additional, Yeniay, L., additional, Utkan, Z., additional, Simsek, T., additional, Karadurmus, N., additional, Daglar, G., additional, Yıldız, B., additional, Uras, C., additional, Tukenmez, M., additional, Yildirim, A.O., additional, Kutun, S., additional, Ozaslan, C., additional, Karaman, N., additional, Akcay, M.N., additional, Toktas, O., additional, and Sezgin, E., additional

Published
2021
Full Text
View/download PDF

6. The role of loco-regional treatment in long-term quality of life in de novo stage IV breast cancer patients: protocol MF07-01Q

Author

Soran, A., Soyder, A., Ozbas, S., Ozmen, V., Karanlik, H., Igci, A., Muslumanoglu, M., Evrensel, T., Canturk, Z., Utkan, Z., Ozaslan, C., Uras, C., Ugurlu, U., Col, C., Cabioglu, N., Uzunkoy, A., Gulluoglu, B.M., Erdem, Ergün, Konca, C., Sezgin, E., and On behalf of Breast Health Working Group International (supported by the Turkish Federation of Breast Disease Societies)

Subjects
Male, Quality of life, Turkish population, medicine.medical_specialty, Activities of daily living, Randomization, Breast Neoplasms, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Breast cancer, Internal medicine, medicine, Humans, 030212 general & internal medicine, Stage (cooking), Stage IV, Neoplasm Staging, business.industry, Middle Aged, medicine.disease, Mental health, humanities, Oncology, 030220 oncology & carcinogenesis, Cohort, Female, De novo, Surgery, business
Abstract

Background/objective: Since more solid evidence has emerged supporting the effectiveness of loco-regional treatment (LRT), clinicians consider LRT a treatment option for selected de novo stage IV breast cancer (BC) patients. This is the first report on long-term quality of life (QoL) in a cohort of patients who were randomized to receive either LRT and then systemic treatment (ST) or ST alone in the protocol MF07-01. We aimed to evaluate QoL in patients living at least 3 years since randomization using scores from the SF-12 health survey. Methods: SF-12 (V2) forms were completed during visits of patients who were living 36 months after the randomization. We first calculated PCS-12 (Physical Health Composite Scale) and MCS-12 (Mental Health Composite Scale) scores from de novo stage IV BC patients and compared them with the scores of patients diagnosed with stage I–III BC who lived more than 3 years. Further, PCS-12 and MCS-12 scores were compared between the LRT and ST groups with de novo stage IV BC. Additionally, general health, physical functioning, role functioning, bodily pain, vitality, mental health, and social functioning were evaluated and compared between the groups. Considering age-related changes in QoL, we also compared PCS-12 and MCS-12 scores of patients below or above 55 and 65 years of age. Responses to four additional questions (compare your physical health, mental health, daily activities, and energy currently vs. at diagnosis of BC) were recorded, considering cultural differences. Results: There were 81 patients in this analysis; 68% of patients (n = 55) had LRT, and 32% (n = 26) received ST. General health was good or very good in 62% (n = 34) in the LRT group and 66% (n = 17) in the ST-only group (p = 0.63). Mean PCS-12 score was 40.8 + 1.6, and mean MCS-12 score was 43.4 + 2.0 (p = 0.34 and p = 0.54, respectively). PCS-12 and MCS-12 score difference was lower than that of the general Turkish population (PCS-12 = 49.3 + 12.8 and MCS-12 = 46.8 + 13.0) and stage I–III BC patients (PCS-12 = 51.1 ± 0.5, MCS-12 = 45.7 ± 0.6). PCS-12 and MCS-12 scores were similar between the LRT and ST-only groups in patients younger and older than 55 and 65, but QoL scores were much better in stage I–III BC patients younger than 65 when compared to the scores of those with de novo stage IV BC. Although treatment with or without LRT did not affect physical health, mental health, daily activities, and energy at 3 years vs. at diagnosis of BC in de novo stage IV BC patients (p > 0.05), these variables were significantly better in stage I–III BC patients (p < 0.001). Conclusion: The current MF07-01Q study demonstrates that patient who had LRT has similar physical and mental health outcomes compared to ST only in a cohort of patients who lived longer than 3 years. Trial registration This study is registered on clinicaltrials.gov with identifier number NCT00557986. © 2020, Springer-Verlag GmbH Germany, part of Springer Nature.

Published
2020

12. Stage IV Breast Cancer at Presentation: Protocol MF07-01

Author

Soran, A, Ozmen, V, Ozbas, S, Karanlik, H, Muslumanoglu, M, Igci, A, Canturk, Z, Utkan, Z, Ozaslan, C, Evrensel, T, Uras, C, Aksaz, E, Soyder, A, Ugurlu, U, Col, C, Cabioglu, N, Bozkurt, B, Uzunkoy, A, Koksal, N, Gulluoglu, BM, Unal, B, Atalay, C, Yildirim, E, Erdem, E, Salimoglu, S, Sezer, A, Koyuncu, A, Gurleyik, G, Alagol, H, Ulufi, N, Berberoglu, U, Dulger, M, Cengiz, O, Sezgin, E, and Johnson, R

Abstract

The MF07-01 trial is a multicenter, phase III, randomized, controlled study comparing locoregional treatment (LRT) followed by systemic therapy (ST) with ST alone for treatment-na < ve stage IV breast cancer (BC) patients. At initial diagnosis, patients were randomized 1:1 to either the LRT or ST group. All the patients were given ST either immediately after randomization or after surgical resection of the intact primary tumor. The trial enrolled 274 patients: 138 in the LRT group and 136 in the ST group. Hazard of death was 34% lower in the LRT group than in the ST group (hazard ratio [HR], 0.66; 95% confidence interval [CI], 0.49-0.88; p = 0.005). Unplanned subgroup analyses showed that the risk of death was statistically lower in the LRT group than in the ST group with respect to estrogen receptor (ER)/progesterone receptor (PR)(+) (HR 0.64; 95% CI 0.46-0.91; p = 0.01), human epidermal growth factor 2 (HER2)/neu(-) (HR 0.64; 95% CI 0.45-0.91; p = 0.01), patients younger than 55 years (HR 0.57; 95% CI 0.38-0.86; p = 0.007), and patients with solitary bone-only metastases (HR 0.47; 95% CI 0.23-0.98; p = 0.04). In the current trial, improvement in 36-month survival was not observed with upfront surgery for stage IV breast cancer patients. However, a longer follow-up study (median, 40 months) showed statistically significant improvement in median survival. When locoregional treatment in de novo stage IV BC is discussed with the patient as an option, practitioners must consider age, performance status, comorbidities, tumor type, and metastatic disease burden.

Published
2018

13. Randomized trial comparing resection of primary tumor with no surgery in stage iv breast cancer at presentation: Protocol mf07-01

Author

Soran, A., Ozmen, V., Ozbas, S., Karanlik, H., Muslumanoglu, M., Igci, A., Canturk, Z., Utkan, Z., Ozaslan, C., Evrensel, T., Uras, C., Aksaz, E., Soyder, A., Ugurlu, U., Col, C., Cabioglu, N., Bozkurt, B., Uzunkoy, A., Koksal, N., Gulluoglu, B.M., Unal, B., Atalay, C., Yıldırım, E., Erdem, Ergün, Salimoglu, S., Sezer, A., Koyuncu, A., Gurleyik, G., Alagol, H., Ulufi, N., Berberoglu, U., Dulger, M., Cengiz, O., Sezgin, E., and Johnson, R.

Subjects
Receptor, ErbB-2, progesterone receptor, systemic therapy, primary tumor, middle aged, Antineoplastic Combined Chemotherapy Protocols, Neoplasm Metastasis, multimodality cancer therapy, antineoplastic agent, comparative study, Mastectomy, bone metastasis, breast tumor, adult, Carcinoma, Ductal, Breast, clinical trial, Prognosis, Combined Modality Therapy, Survival Rate, female, Receptors, Estrogen, Paget nipple disease, secondary, Receptors, Progesterone, estrogen receptor, overall survival, lobular carcinoma, lymph node dissection, Breast Neoplasms, Article, cancer growth, breast cancer, Biomarkers, Tumor, follow up, metastasis, Humans, controlled study, Neoplasm Invasiveness, human, radiotherapy, phase 3 clinical trial, cancer staging, ERBB2 protein, human, tumor invasion, major clinical study, mortality, axillary lymph node, Carcinoma, Lobular, cancer recurrence, multicenter study, tumor marker, randomized controlled trial, epidermal growth factor receptor 2, pathology, metabolism, Follow-Up Studies
Abstract

Background: The MF07-01 trial is a multicenter, phase III, randomized, controlled study comparing locoregional treatment (LRT) followed by systemic therapy (ST) with ST alone for treatment-naïve stage IV breast cancer (BC) patients. Methods: At initial diagnosis, patients were randomized 1:1 to either the LRT or ST group. All the patients were given ST either immediately after randomization or after surgical resection of the intact primary tumor. Results: The trial enrolled 274 patients: 138 in the LRT group and 136 in the ST group. Hazard of death was 34% lower in the LRT group than in the ST group (hazard ratio [HR], 0.66; 95% confidence interval [CI], 0.49–0.88; p = 0.005). Unplanned subgroup analyses showed that the risk of death was statistically lower in the LRT group than in the ST group with respect to estrogen receptor (ER)/progesterone receptor (PR)(+) (HR 0.64; 95% CI 0.46–0.91; p = 0.01), human epidermal growth factor 2 (HER2)/neu(–) (HR 0.64; 95% CI 0.45–0.91; p = 0.01), patients younger than 55 years (HR 0.57; 95% CI 0.38–0.86; p = 0.007), and patients with solitary bone-only metastases (HR 0.47; 95% CI 0.23–0.98; p = 0.04). Conclusion: In the current trial, improvement in 36-month survival was not observed with upfront surgery for stage IV breast cancer patients. However, a longer follow-up study (median, 40 months) showed statistically significant improvement in median survival. When locoregional treatment in de novo stage IV BC is discussed with the patient as an option, practitioners must consider age, performance status, comorbidities, tumor type, and metastatic disease burden. © 2018, Society of Surgical Oncology.

Published
2018

14. The importance of primary surgery in patients with de novo stage IV BC surviving at least 5 years: Protocol MF07-01 randomized clinical trial

Author

Ozmen, V., primary, Ozbas, S., additional, Karanlik, H., additional, Muslumanoglu, M., additional, Igci, A., additional, Canturk, Z., additional, Utkan, Z., additional, Ozaslan, C., additional, Evrensel, T., additional, Uras, C., additional, Aksaz, E., additional, Soyder, A., additional, Ugurlu, U.M., additional, Col, C., additional, Cabioglu, N., additional, Bozkurt, B., additional, Uzunkoy, A., additional, Sezgin, E., additional, Gurleyik, G., additional, and Soran, A., additional

Published
2019
Full Text
View/download PDF

17. Is Breast Conserving Surgery Efficacious in Breast Cancer Patients with BRCA1 or BRCA2 Germline Mutation?

Author

Emiroglu S, Özkurt E, Cabıoglu N, Igci A, Saip P, Yazici H, Ozmen T, Ozmen V, Muslumanoglu M, and Tukenmez M

Subjects
brca1 or brca2 germline mutation, breast conserving surgery, surgical decision, locoregional recurrence., Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Selman Emiroglu,1 Enver Özkurt,2 Neslihan Cab&inodot;oglu,1 Abdullah Igci,3 Pinar Saip,4 Hulya Yazici,4 Tolga Ozmen,5 Vahit Ozmen,1 Mahmut Muslumanoglu,1 Mustafa Tukenmez1 1Breast Surgery Unit, Department of General Surgery, Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey; 2Department of Surgery, Ozel Basari Hospital, Istanbul, Turkey; 3Department of Surgery, American Hospital, Istanbul, Turkey; 4Department of Medical Oncology, Institute of Oncology, Istanbul University, Istanbul, Turkey; 5Division of Gastrointestinal and Oncologic Surgery, Harvard Medical School, Massachusetts General Hospital, Boston, MA, USACorrespondence: Selman Emiroglu, Breast Surgery Service, Department of General Surgery, Istanbul Faculty of Medicine, Istanbul University, Fatih, Istanbul, 34390, Turkey, Email selman.emirikci.82@istanbul.edu.trBackground: The optimal surgical therapy for newly diagnosed breast cancer with germline mutations in susceptibility genes is still uncertain for many physicians. In this study, we aimed to determine the efficacy of breast conserving surgery (BCS) in breast cancer patients with BRCA1 or BRCA2 mutation by assessing its outcomes and locoregional recurrence (LR) rates.Materials and Methods: Seventy-five patients operated with BCS or mastectomy for breast cancer between 2006 and 2017 and had BRCA1 or BRCA2 mutation were included in the study. Effects of the performed breast surgery and clinicopathological characteristics on surgical outcomes, LR rates and survival were analyzed with showing the distribution of BRCA1 and BRCA2 germline mutations.Results: The median age of the patients was 42 years (20– 77). BRCA1 mutations were found in 46 (61.3%) patients and BRCA2 mutations in 29 (38.7%) patients. Compared to BRCA2 carriers, BRCA1 carriers were more likely to have higher tumor grade (84.8% vs 44.8%; p = 0.001) and non-luminal subtype tumors (67.4% vs 13.8%; p = 0.001). A total of 44 (58.7%) patients underwent unilateral mastectomy and 31 (41.3%) patients underwent BCS. At a median follow-up time of 60 (12– 240) months, LR was observed in 6 patients equally divided in both BCS and mastectomy groups. LR rates were slightly higher after BCS versus mastectomy (9.7% and 6.8%, respectively). Additionally, there were no statistically significant differences in disease-free survival (DFS) and disease-specific survival (DSS) rates after 10 years in the BCS group versus the mastectomy group (p = 0.117 and 0.109, respectively), but in fact, the rates were better in the BCS group.Conclusion: Our findings indicate that BCS may serve as an efficacious alternative to mastectomy for breast cancer patients with BRCA1 or BRCA2 mutation. Additionally, tumor size, lymph node positivity, and TNM stage should be taken into consideration for a better surgical decision-making.Keywords: BRCA1 or BRCA2 germline mutation, breast conserving surgery, surgical decision, locoregional recurrence

Published
2023

18. P126 - The effect of primary surgery in patients with stage IV breast cancer with bone metastasis only (protocol bomet MF14-01); a multi-center, registry study

Author

Soran, A., Dogan, L., Ozbas, S., Isık, A., Trablus, D., Demirci, U., Karanlık, H., Soyder, A., Dag, A., Bilici, A., Dogan, M., Koksal, H., Sendur, M.A.N., Gulcelik, M.A., Maralcan, G., Cabioglu, N., Yeniay, L., Utkan, Z., Simsek, T., Karadurmus, N., Daglar, G., Yıldız, B., Uras, C., Tukenmez, M., Yildirim, A.O., Kutun, S., Ozaslan, C., Karaman, N., Akcay, M.N., Toktas, O., and Sezgin, E.

Published
2021
Full Text
View/download PDF

23. Abstract P6-16-01: The importance of loco-regional tumor burden and surgery on survival in patients with de novo stage IV breast cancer; post-hoc analyses of protocol MF07-01

Author

Ozmen, V, primary, Ozbas, S, additional, Karanlik, H, additional, Muslumanoglu, M, additional, Igci, A, additional, Canturk, Z, additional, Utkan, NZ, additional, Ozaslan, C, additional, Evrensel, T, additional, Uras, C, additional, Aksaz, E, additional, Soyder, A, additional, Ugurlu, UM, additional, Col, C, additional, Cabioglu, N, additional, Bozkurt, B, additional, Sezgin, E, additional, Dagoglu, T, additional, Uzunkoy, A, additional, Dulger, M, additional, Koksal, N, additional, Cengiz, O, additional, Gulluoglu, B, additional, Unal, B, additional, Atalay, C, additional, Yildirim, E, additional, Erdem, E, additional, Salimoglu, S, additional, Sezer, A, additional, Koyuncu, A, additional, Gurleyik, G, additional, Alagol, H, additional, Ulufi, N, additional, Berberoglu, U, additional, and Soran, A, additional

Published
2017
Full Text
View/download PDF

34. Abstract S2-03: Early follow up of a randomized trial evaluating resection of the primary breast tumor in women presenting with de novo stage IV breast cancer; Turkish study (protocol MF07-01)

Author

Soran, A, primary, Ozmen, V, additional, Ozbas, S, additional, Karanlik, H, additional, Muslumanoglu, M, additional, Igci, A, additional, Canturk, Z, additional, Utkan, Z, additional, Ozaslan, C, additional, Evrensel, T, additional, Uras, C, additional, Aksaz, E, additional, Soyder, A, additional, Ugurlu, U, additional, Col, C, additional, Cabioglu, N, additional, Bozkurt, B, additional, Dagoglu, T, additional, Uzunkoy, A, additional, Dulger, M, additional, Koksal, N, additional, Cengiz, O, additional, Gulluoglu, B, additional, Unal, B, additional, Atalay, C, additional, Yildirim, E, additional, Erdem, E, additional, Salimoglu, S, additional, Sezer, A, additional, Koyuncu, A, additional, Gurleyik, G, additional, Alagol, H, additional, Ulufi, N, additional, Berberoglu, U, additional, Kennard, E, additional, Kelsey, S, additional, and Lembersky, B, additional

Published
2013
Full Text
View/download PDF

49. Feasibility of surgical management in patients with granulomatous mastitis.

Author

Asoglu O, Ozmen V, Karanlik H, Tunaci M, Cabioglu N, Igci A, Selcuk UE, and Kecer M

Abstract

Granulomatous mastitis (GM) is a rare inflammatory breast disease of unknown etiology. Although it usually presents with sinus formation and abscesses, it may mimic the clinical characteristics of breast cancer. The aim of this study was to identify the clinical, radiologic, and pathologic characteristics of patients with GM and to show the results of surgical treatment in these patients. A chart review was performed for patients that were treated with a diagnosis of GM at the Breast Unit, Department of Surgery, Istanbul Medical Faculty, University of Istanbul, between September 1998 and January 2003. Eighteen patients were eligible for this study. The median age was 41.5 years (range 16-80 years). Seventeen patients were evaluated by both ultrasonography and mammography; whereas one young patient only had ultrasonography. Three patients were further examined with color Doppler ultrasonography and magnetic resonance imaging (MRI). Fourteen patients (78%) presented with a mass as the chief symptom, with a median size of 3.9 cm (range 1-8 cm), whereas four patients presented with fistula in their breasts. None of the radiologic techniques distinguished benign disease from cancer in any of the 14 patients that presented with a mass except one patient with normal mammography findings. Ultrasonography was only helpful to localize the abscess associated with a fistula tract in one patient. Therefore fine-needle aspiration biopsy (FNAB) was performed in six patients, followed by surgical excisional biopsy. The remaining eight patients with a clinical suspicion of malignancy underwent wide surgical excision with frozen section analysis under general anesthesia. All of the FNAB and frozen section evaluations revealed benign findings. All of the 18 patients underwent a wide excisional biopsy and had a definitive histopathologic diagnosis of GM. The median follow-up was 36 months (range 6-60 months). Only one patient had a recurrent disease, which was diagnosed at 12 months. GM is a rare breast disease that mimics cancer in terms of clinical findings. Preoperative radiologic diagnosis might be difficult. Complete surgical excision is the treatment of choice. [ABSTRACT FROM AUTHOR]

Published
2005
Full Text
View/download PDF

50. Successfully treated Mycobacterium abscessusmastitis: A rare cause of breast masses

Author

Yasar, KK, Pehlivanoglu, F, Sengoz, G, and Cabioglu, N

Abstract

Rapidly growing mycobacteria are pathogens responsible for cutaneous or subcutaneous infections especially occurring after injection, trauma or surgery. We describe a patient with Mycobacterium abscessusmastitis that presented as a mass lesion and haemorrhagical discharge. It was initially diagnosed and treated as fibrocystic disease and non-specific abscess. Full recovery was obtained with combination therapy of clarithromycin, linezolid and amikacin without surgical debridement followed by several abscess aspirations. Atypical mycobacteria should be considered in diagnosis of chronic breast lesions in endemic areas. This is the first reported case of mastitis due to M. abscessusin Turkey.

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results